​

Integra LifeSciences (IART) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IART Stock Forecast

Integra LifeSciences (IART) stock forecast, based on 28 Wall Street analysts, predicts a 12-month average price target of $15.80, with a high of $25.00 and a low of $13.00. This represents a 30.58% increase from the last price of $12.10.

$5 $9 $13 $17 $21 $25 High: $25 Avg: $15.8 Low: $13 Last Closed Price: $12.1

IART Stock Rating

Integra LifeSciences stock's rating consensus is Buy, based on 28 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (42.86%), 12 Hold (42.86%), 4 Sell (14.29%), and 0 Strong Sell (0.00%).

Buy
Total 28 0 4 12 12 Strong Sell Sell Hold Buy Strong Buy

IART Price Target Upside V Benchmarks

TypeNameUpside
StockIntegra LifeSciences30.58%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks16.95%

Price Target Trends

1M3M12M
# Anlaysts5610
Avg Price Target$13.80$14.67$16.30
Last Closing Price$12.10$12.10$12.10
Upside/Downside14.05%21.24%34.71%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26127-212
Sep, 26127-212
Aug, 26127-212
Jul, 26125-210
Jun, 26116-210
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2026UBS$14.00$11.9417.25%15.70%
Oct 23, 2026Richard NewitterTruist Financial$13.00$12.018.24%7.44%
Oct 22, 2026Vik ChopraBMO Capital$14.00$11.8518.14%15.70%
Oct 22, 2026Wells Fargo$13.00$11.849.80%7.44%
Oct 03, 2026Larry BiegelsenWells Fargo$15.00$12.6818.30%23.97%
Jul 28, 2026UBS$19.00$19.53-2.71%57.02%
Jul 16, 2026Truist Financial$19.00$19.75-3.80%57.02%
Jul 08, 2026BMO Capital$19.00$17.309.83%57.02%
Jun 18, 2026Argus Research$25.00$17.2045.35%106.61%
Apr 15, 2026Richard NewitterTruist Financial$12.00$11.018.99%-0.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 22, 2026BMO CapitalMarket PerformMarket Performhold
Oct 22, 2026CitigroupOutperformOutperformhold
Oct 22, 2026CitigroupMarket OutperformMarket Outperformhold
Oct 05, 2026CitigroupNeutralNeutralhold
Jul 28, 2026UBSNeutralinitialise
Jul 08, 2026BMO CapitalMarket Performinitialise
Jul 08, 2026CitigroupNeutralNeutralhold
May 28, 2026CitigroupSellNeutralupgrade
Oct 07, 2025CitigroupSellSellhold
Nov 04, 2024CitigroupSellSellhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$2.00$2.18$0.87$-0.09$-6.73--
Avg Forecast$3.18$3.31$3.11$2.45$2.51$2.78$3.38
High Forecast$3.21$3.33$3.12$2.47$2.60$3.64$3.40
Low Forecast$3.14$3.29$3.08$2.43$2.43$1.75$3.35
Surprise %-37.11%-34.14%-72.03%-103.67%-368.13%--

Revenue Forecast

$2B $2B $2B $2B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$1.54B$1.56B$1.54B$1.61B$1.64B--
Avg Forecast$1.54B$1.56B$1.54B$1.61B$1.71B$1.79B$1.94B
High Forecast$1.55B$1.56B$1.55B$1.62B$1.72B$1.79B$1.95B
Low Forecast$1.53B$1.55B$1.53B$1.60B$1.70B$1.79B$1.93B
Surprise %0.14%-0.03%-0.16%-0.17%-4.51%--

Net Income Forecast

$-550M $-380M $-210M $-40M $130M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$169.07M$180.55M$67.74M$-6.94M$-516.47M--
Avg Forecast$144.29M$161.85M$67.74M$196.95M$202.38M$216.78M$271.54M
High Forecast$173.14M$194.22M$81.29M$198.56M$209.25M$292.79M$273.45M
Low Forecast$115.43M$129.48M$54.19M$195.34M$195.52M$140.76M$269.14M
Surprise %17.18%11.55%--103.53%-355.20%--

IART Forecast FAQ

Is Integra LifeSciences stock a buy?

Integra LifeSciences stock has a consensus rating of Buy, based on 28 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 12 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that Integra LifeSciences is a favorable investment for most analysts.

What is Integra LifeSciences's price target?

Integra LifeSciences's price target, set by 28 Wall Street analysts, averages $15.8 over the next 12 months. The price target range spans from $13 at the low end to $25 at the high end, suggesting a potential 30.58% change from the previous closing price of $12.1.

How does Integra LifeSciences stock forecast compare to its benchmarks?

Integra LifeSciences's stock forecast shows a 30.58% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (16.95%).

What is the breakdown of analyst ratings for Integra LifeSciences over the past three months?

  • October 2026: 8.33% Strong Buy, 16.67% Buy, 58.33% Hold, 0% Sell, 16.67% Strong Sell.
  • September 2026: 8.33% Strong Buy, 16.67% Buy, 58.33% Hold, 0% Sell, 16.67% Strong Sell.
  • August 2026: 8.33% Strong Buy, 16.67% Buy, 58.33% Hold, 0% Sell, 16.67% Strong Sell.

What is Integra LifeSciences’s EPS forecast?

Integra LifeSciences's average annual EPS forecast for its fiscal year ending in December 2026 is $2.78, marking a -141.31% decrease from the reported $-6.73 in 2025. Estimates for the following years are.

What is Integra LifeSciences’s revenue forecast?

Integra LifeSciences's average annual revenue forecast for its fiscal year ending in December 2026 is $1.79B, reflecting a 9.29% increase from the reported $1.64B in 2025. The forecast for.

What is Integra LifeSciences’s net income forecast?

Integra LifeSciences's net income forecast for the fiscal year ending in December 2026 stands at $216.78M, representing a -141.97% decrease from the reported $-516M in 2025. Projections indicate .